DIVISLAB - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 4.0
| Stock Code | DIVISLAB | Market Cap | 1,79,262 Cr. | Current Price | 6,753 ₹ | High / Low | 7,078 ₹ |
| Stock P/E | 67.3 | Book Value | 629 ₹ | Dividend Yield | 0.44 % | ROCE | 22.4 % |
| ROE | 16.8 % | Face Value | 2.00 ₹ | DMA 50 | 6,576 ₹ | DMA 200 | 6,357 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.05 % | PAT Qtr | 756 Cr. | PAT Prev Qtr | 653 Cr. |
| RSI | 55.1 | MACD | 26.8 | Volume | 3,84,571 | Avg Vol 1Wk | 3,22,409 |
| Low price | 5,636 ₹ | High price | 7,078 ₹ | PEG Ratio | 4.87 | Debt to equity | 0.00 |
| 52w Index | 77.5 % | Qtr Profit Var | 13.3 % | EPS | 98.2 ₹ | Industry PE | 32.5 |
Divi’s Laboratories shows strong fundamentals with excellent ROCE and ROE, zero debt, and consistent profit growth. Technically, the stock is trading above both its 50 DMA and 200 DMA, with RSI at 55.1 and MACD positive, indicating bullish momentum. However, the very high P/E ratio compared to industry average and elevated PEG ratio suggest valuation concerns. Overall, it is a good candidate for swing trading with moderate upside potential.
💡 Optimal Entry Price: Around 6,600–6,700 ₹ (near support levels close to DMA 50).
📈 Exit Strategy: If already holding, consider booking profits near 7,050–7,100 ₹ (recent highs) or exit if price falls below 6,550 ₹ (DMA 50 support).
✅ Positive
- 📈 Strong ROCE at 22.4% and ROE at 16.8% show efficient capital use.
- 💰 Zero debt-to-equity ratio ensures financial stability.
- 📊 PAT growth from 653 Cr. to 756 Cr. (+13.3%) quarter-on-quarter.
- 📉 Price trading above DMA 50 and DMA 200, confirming bullish trend.
⚠️ Limitation
- 📉 Very high P/E ratio of 67.3 compared to industry average of 32.5.
- 📉 Elevated PEG ratio at 4.87 suggests valuation concerns relative to growth.
- 📉 Dividend yield at 0.44% is modest.
📰 Company Negative News
- 📉 Decline in DII holding (-0.05%) shows reduced domestic institutional support.
🌟 Company Positive News
- 📈 Increase in FII holding (+0.21%) signals strong foreign investor confidence.
- 📊 Consistent quarterly profit growth boosts investor sentiment.
🏭 Industry
- 📊 Industry P/E at 32.5, lower than Divi’s Laboratories’ 67.3, suggesting sector is moderately valued while the stock is expensive.
- 📈 Pharmaceuticals industry remains resilient with long-term demand growth.
📌 Conclusion
Divi’s Laboratories presents a solid swing trade opportunity. Excellent fundamentals, zero debt, and bullish technicals make it attractive, though high valuation requires caution. Entry is favorable near 6,600–6,700 ₹, with profit booking advised around 7,050–7,100 ₹. Risk management is essential due to valuation premium.